Virginia Retirement Systems ET AL increased its stake in shares of Homology Medicines, Inc. (NASDAQ:FIXX – Get Rating) by 55.2% during the 4th quarter, Holdings Channel reports. The fund owned 25,600 shares of the company’s stock after acquiring an additional 9,100 shares during the period. Virginia Retirement Systems ET AL’s holdings in Homology Medicines were worth $93,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Temasek Holdings Private Ltd increased its stake in Homology Medicines by 72.7% in the third quarter. Temasek Holdings Private Ltd now owns 5,650,996 shares of the company’s stock valued at $44,473,000 after purchasing an additional 2,378,418 shares in the last quarter. Morgan Stanley grew its stake in shares of Homology Medicines by 604.2% in the 2nd quarter. Morgan Stanley now owns 224,866 shares of the company’s stock valued at $1,634,000 after buying an additional 192,936 shares during the period. Two Sigma Investments LP bought a new stake in Homology Medicines in the 3rd quarter valued at about $1,268,000. BlackRock Inc. raised its stake in Homology Medicines by 3.4% during the 3rd quarter. BlackRock Inc. now owns 3,471,030 shares of the company’s stock worth $27,316,000 after buying an additional 112,893 shares during the period. Finally, Panagora Asset Management Inc. boosted its holdings in Homology Medicines by 10,900.8% in the third quarter. Panagora Asset Management Inc. now owns 90,647 shares of the company’s stock worth $713,000 after acquiring an additional 89,823 shares in the last quarter. Institutional investors and hedge funds own 55.77% of the company’s stock.
FIXX opened at $1.78 on Friday. Homology Medicines, Inc. has a fifty-two week low of $1.76 and a fifty-two week high of $8.90. The firm has a market capitalization of $102.15 million, a P/E ratio of -1.05 and a beta of -0.59. The company’s 50-day moving average is $2.97 and its 200 day moving average is $4.13.
Several equities research analysts have recently commented on FIXX shares. FIX decreased their price objective on Homology Medicines from $19.00 to $7.00 in a report on Wednesday, April 6th. Chardan Capital restated a “buy” rating on shares of Homology Medicines in a research note on Tuesday, March 29th. BTIG Research dropped their price objective on shares of Homology Medicines from $35.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 22nd. Zacks Investment Research downgraded shares of Homology Medicines from a “buy” rating to a “hold” rating in a research report on Monday, March 28th. Finally, Bank of America dropped their price target on shares of Homology Medicines from $25.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday, February 22nd. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Homology Medicines currently has an average rating of “Buy” and a consensus price target of $13.75.
About Homology Medicines (Get Rating)
Homology Medicines, Inc, a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders.
- Get a free copy of the StockNews.com research report on Homology Medicines (FIXX)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.